| Title |
Phase II, Open-Label, Multi-centre, 2-part Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) Unfit for Conventional Chemotherapy ( >18 Years) or in Patients With Acute Myeloid Leukemia in First Relapse ( >60 Years) |
| Scientific Title |
Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia |
| Short Title |
AML HEMOS 0106 |
| Trialgroup |
NN |
| Type of Trial |
open-label, multicentric |
| Disease |
Acute myeloic leukemia(AML) AML all subtypes without FAB M3
|
| Age |
>= 18 years |
| Status |
Active |
| Start of Recruitment |
02.08.2007 |
| Leader |
Martinelli, MD, Giovanni |
| Contactperson |
principal investigator
Martinelli, MD, Giovanni
Tel: +39 (0)51 6363829
Email: gmartino@alma.unibo.it
|
| Shortprotocol |
Shortprotocol |
created 